These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 33847661

  • 1. A pilot study on EORTC or PERCIST for the prediction of progression-free survival with nivolumab therapy in advanced or metastatic gastric cancers: A STROBE-compliant article.
    Nakajo M, Kitajima K, Toriihara A, Arigami T, Daisaki H, Nakamura A, Ohtsuka T, Miwa H, Yoshiura T.
    Medicine (Baltimore); 2021 Apr 16; 100(15):e25494. PubMed ID: 33847661
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT.
    Park S, Lee Y, Kim TS, Kim SK, Han JY.
    Medicine (Baltimore); 2020 Dec 18; 99(51):e23815. PubMed ID: 33371161
    [Abstract] [Full Text] [Related]

  • 6. Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
    Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2021 Jun 18; 48(6):1932-1943. PubMed ID: 33336264
    [Abstract] [Full Text] [Related]

  • 7. FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.
    Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A.
    PLoS One; 2018 Jun 18; 13(7):e0199529. PubMed ID: 30011328
    [Abstract] [Full Text] [Related]

  • 8. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H.
    Eur J Nucl Med Mol Imaging; 2016 Oct 18; 43(11):1945-53. PubMed ID: 27236466
    [Abstract] [Full Text] [Related]

  • 9. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Ho KC, Fang YD, Chung HW, Liu YC, Chang JW, Hou MM, Yang CT, Cheng NM, Su TP, Yen TC.
    Eur J Nucl Med Mol Imaging; 2016 Nov 18; 43(12):2155-2165. PubMed ID: 27260520
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
    Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, Guminski AD, Long GV, Menzies AM.
    Ann Oncol; 2018 Oct 01; 29(10):2115-2120. PubMed ID: 30137228
    [Abstract] [Full Text] [Related]

  • 13. Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment.
    Önner H, Eren OÖ, Körez MK, Yilmaz F, Kara Gedik G.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023 Oct 01; 42(5):319-324. PubMed ID: 37030597
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
    Dhull VS, Sharma P, Sharma DN, Maharjan S, Suman Kc S, Patel C, Bal C, Kumar R.
    Int J Gynecol Cancer; 2014 Feb 01; 24(2):312-20. PubMed ID: 24407578
    [Abstract] [Full Text] [Related]

  • 16. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
    Lian W, Liu C, Gu B, Zhang J, Lu L, Pan H, Yao Z, Wang M, Song S, Zhang Y, Yang Z.
    Nucl Med Commun; 2020 Mar 01; 41(3):280-287. PubMed ID: 32032193
    [Abstract] [Full Text] [Related]

  • 17. Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F.
    J Nucl Med; 2020 Jul 01; 61(7):990-998. PubMed ID: 31806768
    [Abstract] [Full Text] [Related]

  • 18. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
    Amrane K, Le Goupil D, Quere G, Delcroix O, Gouva S, Schick U, Salaun PY, Abgral R, Alavi Z, Keromnes N, Querellou S.
    Medicine (Baltimore); 2019 Jul 01; 98(29):e16417. PubMed ID: 31335691
    [Abstract] [Full Text] [Related]

  • 19. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.
    Kim JE, Chae SY, Kim JH, Kim HJ, Kim TW, Kim KP, Kim SY, Lee JL, Oh SJ, Kim JS, Ryu JS, Moon DH, Hong YS.
    Eur J Nucl Med Mol Imaging; 2019 Jul 01; 46(8):1713-1722. PubMed ID: 31041456
    [Abstract] [Full Text] [Related]

  • 20. The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy.
    Nakajo M, Kitajima K, Kaida H, Morita T, Minamimoto R, Ishibashi M, Yoshiura T.
    Clin Radiol; 2020 Jan 01; 75(1):79.e9-79.e18. PubMed ID: 31662200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.